Tactile Systems Technology Inc. (NASDAQ: TCMD) achieved a new 52-week high in premarket trading, with shares advancing 23.35% following the release of strong fourth-quarter financial results and the announcement of a strategic acquisition. The medical device company reported fourth-quarter earnings per share of $0.46, exceeding analyst consensus of $0.44, while quarterly revenue reached $103.59 million, representing 21% year-over-year growth and surpassing Wall Street estimates of $93.80 million.
The company's momentum was further bolstered by its acquisition of LymphaTech for $6.8 million, a transaction designed to strengthen its portfolio in lymphedema treatment solutions. The purchase expands Tactile Systems' therapeutic offerings within its existing market focus and aligns with the company's growth strategy in the chronic disease management sector.
Looking ahead, Tactile Systems provided guidance for fiscal 2026 that exceeded market expectations, projecting revenues between $357 million and $365 million alongside adjusted EBITDA in the range of $49 million to $51 million. The forward guidance reflects management's confidence in sustained operational momentum and the integration of recently acquired capabilities.